Abstract
Ischemic stroke, a prevalent neurological disease, is the major reason of serious disability and death worldwide. Methylene-tetrahydrofolate reductase (MTHFR) gene polymorphisms increase homocysteine levels which also raise the risk of vascular diseases. Angiotensin-converting enzyme (ACE) gene polymorphisms can cause vascular reorganization and disrupt arterial wall stability. The aim of this study was to explore how the MTHFR and ACE gene polymorphisms are related to acute ischemic stroke. A total of 200 individuals (102 acute ischemic stroke patients and 98 healthy controls) were included in this case–control research. MTHFR gene C677T (rs1801133) and A1298C (rs1801131) polymorphisms were studied through polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) assays, ACE gene I/D polymorphism (rs1799752) was studied by PCR. The MTHFR C667T and ACE I/D polymorphisms did not show any statistically meaningful differences between healthy controls and acute ischemic stroke patients (P > 0.05). However, compared to healthy controls, acute ischemic stroke patients had almost nine-fold higher prevalence of the CC genotype based on the MTHFR A1298C polymorphism (P=0.024, OR=8.8, 95%Cl=1.27–208.2). Additionally, individuals with acute ischemic stroke had greater frequencies of the combined genotypes of MTHFR and ACE gene polymorphisms in the forms of CC/CC (C667T/A1298C), CC/DD (A1298C/ACE I/D) and CC/CC/DD (C677T/A1298C/ACE I/D) (P = 0.027, P = 0.015 and P = 0.037, respectively). A statistically significant correlation was assessed between MTHFR gene A1298C polymorphism and acute ischemic stroke. Additionally, it was discovered that the genotype combinations of CC/CC (C667T/A1298C), CC/DD (A1298C/ACE I/D) and CC/CC/DD (C677T/A1298C/ACE I/D) have risk-increasing effects on acute ischemic stroke. To employ these genetic variations as alternative treatments for ischemic stroke, these findings should be validated by more research.
Similar content being viewed by others
References
Akar N., Akar E., Ozel D., Deda G. and Sipahi T. 2001 Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb. Res. 102, 115–120.
Alberts M. J. 1999 Diagnosis and treatment of ischemic stroke. Am. J. Med. 106, 211–221.
Ay C., Bencur P., Vormittag R., Sailer T., Jungbauer C., Vukovich T. et al. 2007 The angiotensinconverting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. Data from a case control study. Thromb. Haemost. 98, 777–782.
Bailey L. B. and Gregory J. F. I. I. I. 1999 Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J. Nutr. 129, 919–922.
Boushey C. J., Beresford S. A., Omenn G. S. and Motulsky A. G. 1995 A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049–1057.
Celiker G., Can U., Verdi H., Yazici A. C., Ozbek N. and Atac F. B. 2009 Prevalence of thrombophilic mutations and ACE I/D polymorphism in Turkish ischemic stroke patients. Clin. Appl. Thromb. Hemost. 15, 415–420.
Chrysant S. G. 1998 Vascular remodeling: the role of angiotensinconverting enzyme inhibitors. Am. Heart J. 135, S21-30.
Çilingir V., Milanlıoğlu A. and Tombul T. 2014 Ishemic stroke in a young man with MTHFR A1298C and ACE I/D polymorphism. Turk. J. Cerebrovasc. Dis. 20, 73–76.
Dikmen M., Ozbabalik D., Gunes H. V., Degirmenci I., Bal C., Ozdemir G. et al. 2006a Acute stroke in relation to homocysteine and methylenetetrahydrofolate reductase gene polymorphisms. Acta Neurol. Scand. 113, 307–314.
Dikmen M., Günes H. V., Degirmenci I., Ozdemir G. and Basaran A. 2006b Are the angiotensinconverting enzyme gene and activity risk factors for stroke? Arq. Neuropsiquiatr. 64, 211–216.
Dong X., Wang J., Wang G., Wang J., Wang L. and Du Y. 2021 MTHFR A1298C gene polymorphism on stroke risk: an updated meta-analysis. Genes Environ. 43, 40.
Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G. et al. 1995 A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10, 111–113.
Homocysteine Studies Collaboration 2002 Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015–2022.
Humphries S. E. and Morgan L. 2004 Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol. 3, 227–235.
Goyette P., Sumner J. S., Milos R., Duncan A. M., Rosenblatt D. S., Matthews R. G. et al. 1994 Human methylenetetrahydrofolate reductase: isolation of cDNA, map** and mutation identification. Nat. Genet. 7, 195–200.
Goyette P., Pai A., Milos R., Frosst P., Tran P., Chen Z. et al. 1998 Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm. Genome 9, 652–656.
Jeunemaitre X., Lifton R. P., Hunt S. C., Williams R. R. and Lalouel J. M. 1992 Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat. Genet. 1, 72–75.
Karakus N., Duygu F., Rustemoglu A. and Yigit S. 2022 Methylene-tetrahydrofolate reductase gene C677T and A1298C polymorphisms as a risk factor for Crimean-Congo hemorrhagic fever. Nucleosides Nucleotides Nucleic Acids 41, 878–890.
Mozaffarian D., Benjamin E. J., Go A. S., Arnett D. K., Blaha M. J., Cushman M. et al. 2016 Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133, e38-360.
Pezzini A., Grassi M., Del Zotto E., Archetti S., Spezi R., Vergani V. et al. 2005 Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults. Stroke 36, 533–539.
Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P. and Soubrier F. 1990 An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343–1346.
Rigat B., Hubert C., Corvol P. and Soubrier F. 1992 PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidylcarboxypeptidase 1). Nucleic Acids Res. 20, 1433.
Rosenblatt D. S. 2001 Methylenetetrahydrofolate Reductase. Clin. Invest. Med. 24, 56–59.
Sazci A., Ergul E., Tuncer N., Akpinar G. and Kara I. 2006 Methylenetetrahydrofolate reductase gene polymorphisms are associated with ischemic and hemorrhagic stroke: dual effect of MTHFR polymorphisms C677T and A1298C. Brain Res. Bull. 71, 45–50.
Slowik A., Turaj W., Dziedzic T., Haefele A., Pera J., Malecki M. T. et al. 2004 DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. Neurology 63, 359–361.
Strong K., Mathers C. and Bonita R. 2007 Preventing stroke: saving lives around the world. Lancet Neurol. 6, 182–187.
Tascilar N., Dursun A., Ankarali H., Mungan G., Ekem S. and Baris S. 2009 Angiotensin-converting enzyme insertion/deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension. J. Neurol. Sci. 285, 137–141.
Tiret L., Rigat B., Visvikis S., Breda C., Corvol P., Cambien F. et al. 1992 Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. 51, 197–205.
Tuncer N., Tuglular S., Kiliç G., Sazci A., Us O. and Kara I. 2006 Evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischaemic stroke. J. Clin. Neurosci. 13, 224–227.
van der Put N. M., Gabreëls F., Stevens E. M., Smeitink J. A., Trijbels F. J., Eskes T. K. et al. 1998 A second mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 62, 1044–1051.
Wei L. K., Au A., Menon S., Griffiths L. R., Kooi C. W., Irene L. et al. 2017 Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis. J. Stroke Cerebrovasc. Dis. 26, 2482–2493.
Yuan H., Wang X., **a Q., Ge P., Wang X. and Cao X. 2016 Angiotensin converting enzyme (I/D) gene polymorphism contributes to ischemic stroke risk in Caucasian individuals: a meta-analysis based on 22 case-control studies. Int. J. Neurosci. 126, 488–498.
Zhao J., Qin X., Li S. and Zeng Z. 2014 Association between the ACE I/D polymorphism and risk of ischemic stroke: an updated meta-analysis of 47,026 subjects from 105 case-control studies. J. Neurol. Sci. 345, 37–47.
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: Durgadas P. Kasbekar
Rights and permissions
About this article
Cite this article
Karakus, N., Yigit, S., Basol, N. et al. Dual effect of methylene-tetrahydrofolate reductase and angiotensin-converting enzyme gene polymorphisms on the risk of acute ischemic stroke. J Genet 102, 29 (2023). https://doi.org/10.1007/s12041-023-01425-x
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12041-023-01425-x